Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04809350
Other study ID # REB20-2139
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 10, 2023
Est. completion date May 31, 2025

Study information

Verified date November 2023
Source University of Calgary
Contact Belal N Alshaikh, MD, MSc
Phone 4039561588
Email balshaik@ucalgary.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Research question: Do preterm infants born <1250 g achieve better weight gain with targeted fortification compared with the adjustable fortification of human milk? Hypothesis: Targeted fortification of human milk results in better weight gain in infants with birth weight <1250 gr when compared to the adjustable fortification. Study design: Open-label, pragmatic, parallel randomized controlled trial in appropriate for gestational age infants with birth weight <1250 g.


Description:

Human milk is the ideal diet for neonates. However, it does not provide enough energy, protein, and sodium to meet the nutritional requirements of very preterm infants. Postnatal growth failure is common despite the current use of human milk fortifiers. The main human milk fortification methods include: 1. standard HM fortification (SF) which assumes an average composition of breast milk and adds fortifiers in a fixed dosage. It does not account for variations of nutrient content in human milk 2. Individualized human milk fortification which encompasses two methods: 1. Adjustable HM fortification (AF): Protein supplementation is provided in addition to SF according to blood urea nitrogen (BUN) concentration which reflects the infant's metabolic response to protein intake. However, there are clinical scenarios in which the BUN levels are not a reliable marker of protein intake, such as acute kidney injury. 2. Targeted HM fortification (TF): Based on routine analyses of HM that are used to adjust fortification to meet the recommended requirements for infants. It does not take into consideration that the requirements of infants may vary. SF has frequently failed to achieve appropriate weight gain, while individualized (AF or TF) fortification seems to have better performance. However, the evidence to support one method over the other is lacking. The objective of the study is to compare weekly average weight gain between preterm infants on AF versus TF. Once the written consent is obtained, the infant will be randomized to AF or TF. The sequence code will be kept in sequential numbered sealed envelopes. Infants from multiple births will be included as 1 unit and randomized to the same arm of the study. For patients allocated to the TF group, breast milk will be analyzed twice weekly for energy, protein, and sodium contents. The daily protein, fat, and sodium intakes will be then calculated and optimized to meet the recommended dietary reference intake (DRI) for preterm infants with birth weight <1250 g. For patients allocated to the AF group, weekly BUN measurements will be performed. Based on BUN concentrations, the liquid protein will be added to achieve the targeted BUN level. Additional calories will be added using formula if growth is suboptimal or DRI is not met based on the assumed human milk content for protein and energy. The intervention will last 4-8 weeks. For all patients, the day the first BUN concentration and milk analyses are done will be day 1 of intervention. The following measurements will be performed on days 7-8, 14-16, 21-23, and 28-30 of intervention: Weight (grams), length and head circumference (centimeters), BUN and sodium concentrations. Data on maternal and neonatal characteristics will be collected from their electronic and physical charts.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date May 31, 2025
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Infants with birth weight <1250 g born at Foothills Medical Centre. - Appropriate for gestational age (AGA) (according to Fenton's Charts). Exclusion Criteria: - Abnormal Newborn Metabolic Screen - Major congenital anomalies intervention. - Patients who develop NEC prior to enrollment. - Patients with confirmed congenital Toxoplasmosis, Syphilis, Rubella, Cytomegalovirus, Herpes simplex virus, Varicella and/or Zika (TORCH infections). - Patients receiving systemic steroids. - Patients with acute kidney injury (AKI).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Adjustable Human Milk Fortification
BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk. Liquid protein will be added based on serum urea.
Targeted Human Milk Fortification
Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital. Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes.

Locations

Country Name City State
Canada Foothills Medical Centre Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average weight gain in infants on Adjustable versus Targeted human milk fortification Average weight gain measured as g/kg per day Weekly for 8 weeks
Secondary Anthropometrics in infants on Adjustable versus Targeted human milk fortification Measurement of head circumference and length in centimeters. Weekly for 8 weeks
Secondary BUN concentration in infants on Adjustable versus Targeted human milk fortification mmol/L Weekly for 4 weeks
Secondary Incidence of extra uterine growth restriction Defined as weight less than 10th percentile at 36 weeks corrected age (CA) At 36 weeks CA
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04226586 - Nutritional Stimulation of Growth in Children With Short Stature N/A
Terminated NCT03016195 - Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies N/A
Active, not recruiting NCT01809548 - Preterm Infants on Early Solid Foods N/A
Completed NCT01475357 - Intestinal Function in Neonates With Complex Congenital Heart Disease N/A
Completed NCT02136966 - Joint Infant and Young Child Nutrition Program and Malnutrition Prevention N/A
Active, not recruiting NCT04565314 - ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth N/A
Completed NCT02515266 - Additional Protein Fortification in Extremely Low Birth Weight Infants N/A
Recruiting NCT04294368 - Targeted Fortification of Donor Breast Milk in Preterm Infants N/A
Terminated NCT03532555 - Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia N/A
Withdrawn NCT02999945 - Optimal Growth of Preterm Infants With Growth Restriction N/A
Completed NCT01909661 - Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas Phase 2
Not yet recruiting NCT04640805 - Targeted Fortification of Pasteurized Donor Human Milk N/A
Completed NCT01603368 - Prophylactic Probiotics to Extremely Low Birth Weight Prematures Phase 2
Withdrawn NCT01314508 - Increlex Treatment of Children With Chronic Liver Disease and Short Stature N/A
Terminated NCT00490100 - Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Phase 1/Phase 2
Completed NCT04587271 - Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children N/A
Completed NCT01034735 - r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Phase 1
Active, not recruiting NCT03761498 - Is There a Microbiome Associated With Poor Growth in Preterm Infants?
Not yet recruiting NCT03522558 - Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting N/A
Completed NCT03563391 - A Study to Evaluate the Effects of a New Formula on the Growth, Safety and Tolerance of Infants With Growth Failure N/A